Last updated: July 3, 2026
TOLMAR THERAPEUTICS v. FORESEE PHARMACEUTICALS Co. Ltd. (D.N.J. Case 2:21-cv-15782-EP-CLW): Litigation Summary, Case Posture, and Patent/Risk Analysis
Executive summary: The docket for Tolmar Therapeutics, Inc. v. Foresee Pharmaceuticals Co., Ltd., No. 2:21-cv-15782-EP-CLW (D.N.J.) concerns a patent infringement dispute tied to a Hatch-Waxman-style FDA/ANDA generic-development context. The public record volume available in standard reporting for this specific docket does not provide enough complete, case-specific information here to accurately identify the asserted patents, the FDA application(s) at issue, the filing dates and statutory notice basis (e.g., Paragraph IV vs. other), the claims for each party, the presence/absence and substance of any stipulations or settlements, or the current disposition status on the merits.
Because this request requires a litigation summary and analysis with case-accurate details, including hard datapoints (asserted patents, key filings, holdings, and outcome), and because those facts are not fully available in the information provided in the prompt, producing a complete and accurate litigation analysis would risk inserting incorrect specifics.
What patents are asserted in Tolmar Therapeutics v. Foresee Pharmaceuticals Co. Ltd. 2:21-cv-15782?
Featured snippet answer: Not determinable from the information provided.
Which patent numbers and jurisdictions does the case target?
Not determinable from the information provided.
Are method-of-use, formulation, or composition-of-matter patents asserted?
Not determinable from the information provided.
What is the procedural posture of 2:21-cv-15782-EP-CLW (motions, hearings, and rulings)?
Featured snippet answer: Not determinable from the information provided.
Were there early Rule 12 challenges (personal jurisdiction, venue, standing) or claim construction phases?
Not determinable from the information provided.
Has the court issued claim construction, summary judgment, or trial outcomes?
Not determinable from the information provided.
When was FDA ANDA or 505(b)(2) litigation timing triggered in this case?
Featured snippet answer: Not determinable from the information provided.
Does the complaint allege a Paragraph IV certification?
Not determinable from the information provided.
Was there a settlement-triggered launch date or regulatory stay (30/60-month stay)?
Not determinable from the information provided.
What is the Orange Book status and how does it tie to the asserted patents in this docket?
Featured snippet answer: Not determinable from the information provided.
Which product label and dosage form are implicated (strength, route, formulation)?
Not determinable from the information provided.
Who is listed as reference listed drug (RLD) and patent holder in the Orange Book for the relevant product?
Not determinable from the information provided.
How strong is the patent estate at issue in Tolmar v. Foresee (validity and infringement risk)?
Featured snippet answer: Not determinable from the information provided.
What defenses did Foresee typically raise in this posture (invalidity, non-infringement, prosecution history estoppel)?
Not determinable from the information provided.
Were there design-around or label carve-out arguments tied to equivalence or claim scope?
Not determinable from the information provided.
What settlement terms or consent judgments affect generic entry risk for Foresee?
Featured snippet answer: Not determinable from the information provided.
Was there a covenant-not-to-sue, stipulated dismissal, or final judgment?
Not determinable from the information provided.
What launch timing outcomes followed from any resolution?
Not determinable from the information provided.
How does this dispute compare with other Tolmar patent litigations against generic entrants?
Featured snippet answer: Not determinable from the information provided.
Are there recurring asserted patent families or common claim themes across Tolmar suits?
Not determinable from the information provided.
What generic entry risks exist for Foresee depending on the outcome of 2:21-cv-15782?
Featured snippet answer: Not determinable from the information provided.
If patents were upheld, what would be the practical consequence for FDA approval and commercialization?
Not determinable from the information provided.
If patents were invalidated or not infringed, what would be the likely path to market?
Not determinable from the information provided.
Key Takeaways
- No complete, docket-specific litigation facts (asserted patents, FDA application details, filings, rulings, or outcome) are provided or available in the prompt to support a correct summary and analysis for Tolmar Therapeutics, Inc. v. Foresee Pharmaceuticals Co., Ltd., No. 2:21-cv-15782-EP-CLW.
FAQs
- Is Tolmar v. Foresee a Paragraph IV litigation under 21 U.S.C. § 355(j)?
Not determinable from the information provided.
- What did the court decide on infringement in docket 2:21-cv-15782-EP-CLW?
Not determinable from the information provided.
- Did the parties enter a settlement that affects FDA launch timing?
Not determinable from the information provided.
- Which specific patents were asserted and what claim types did they cover?
Not determinable from the information provided.
- What is the current status of the case as of the last public filing?
Not determinable from the information provided.
References
- Not available from the information provided in the prompt.
